Neuroimmunological diseases and their treatment compromise the immune system, thereby
increasing the risk of infections and serious illness. Consequently, vaccinations to protect …

Abstract Introduction Responses to SARS‐CoV‐2 vaccination in patients with MS (pwMS)
varies by disease‐modifying therapies (DMTs). We perform a meta‐analysis and systematic …

Cladribine tablets (CladT) is a highly active oral disease-modifying therapy (DMT) for the
management of relapsing multiple sclerosis (RMS). CladT acts as an immune reconstitution …

Multiple sclerosis (MS) is a chronic, progressive neurological disease involving
neuroinflammation, neurodegeneration, and demyelination. Cladribine tablets are approved …

Multiple sclerosis (MS) is a chronic, progressive, inflammatory disorder of the central
nervous system. Relapsing–remitting MS (RRMS), the most common form of the disease, is …

Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system,
characterized by chronic, inflammatory, demyelinating, and neurodegenerative processes …

According to current knowledge, the etiopathogenesis of multiple sclerosis (MS) is complex,
involving genetic background as well as several environmental factors that result in …

Background Multiple sclerosis (MS) patients receive immunomodulatory treatments which
can influence their ability to maintain vaccine specific serological response overtime. MS …

Immune responses in people with multiple sclerosis (pwMS) receiving disease-modifying
therapies (DMTs) have been of significant interest throughout the COVID-19 pandemic …

Introduction There are no reports in LATAM related to longitudinal humoral and cellular
response to adenovirus based COVID-19 vaccines in people with Multiple Sclerosis (pwMS) …